Publications
These non-promotional scientific presentations were presented at the medical congresses referenced below and are intended for U.S healthcare professionals who were in attendance for the purposes of scientific exchange.
These materials may contain information outside of the FDA approved label or relate to uses that have not been approved by the FDA. Syndax does not recommend use of Syndax products in any manner other than as described in the FDA-approved Prescribing Information.
Menin-MLL inhibitors enhance JUND activity in MLLr leukemic cells contributing to tumorigenesis and therapy resistance
PMID: 42371796
Immunophenotypic changes following menin inhibition in acute myeloid leukemia
PMID: 41814014
Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms
PMID: 42425075
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
PMID: 42272166
CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials
PMID: 42103719
Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease
PMID: 40536163
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
PMID: 40332046
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
PMID: 40504618
Budget impact analysis of revumenib for the treatment of relapsed or refractory acute leukemias with a KMT2A translocation in the United States
PMID: 40459635